Digest Network Come funziona
Network
/
Società
Ca
Non verificato

Camurus AB

Di cosa scriviamo

FarmaceuticaFitnessMedicina - VarieSaluteSanità

7 comunicati stampa

Guarda tutti i comunicati
17/07/2026
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
01/06/2026
Salute
Fitness
Mercato del lavoro
Legge/Diritto
Fisco/Tributi
Medicina - Varie
Camurus announces expansion of Lilly collaboration
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
01/07/2025
Salute
Fitness
Medicina - Varie
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
03/06/2025
Farmaceutica
Sanità
Economia
Brevetti, marchi e copyright
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
25/04/2025
Farmaceutica
Sanità
Biologia
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
15/07/2024
Farmaceutica
Sanità
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0
25/06/2024
Farmaceutica
Sanità
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Fonte
Camurus AB
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0